

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586


Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2019

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 31/03/2019	3 months ended 31/12/2018	3 months ended 31/03/2018	12 months ended 31/03/2019	12 months ended 31/03/2018
		Audited	Unaudited	Audited	Audited	Audited
(1)	(2)	(3)	(4)	(5)	(6)	(7)
I.	Revenue from operations	8,304.94	6,999.91	6,710.89	32,066.43	24,124.72
II.	Other income	84.23	123.99	153.21	470.19	737.85
III.	Total Revenue (I + II)	8,389.17	7,123.90	6,864.10	32,536.62	24,862.56
IV.	Expenses:					
	Cost of materials consumed	6,156.63	5,728.52	5,157.69	24,548.95	18,372.29
	Purchases of Stock-in-Trade	-	235.26	24.65	366.96	34.62
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	197.96	(596.62)	(135.94)	(621.95)	(327.74)
	Employee benefits expense	265.32	237.04	251.24	1,014.03	890.42
	Finance costs	6.68	7.98	3.61	17.10	4.05
	Depreciation and amortization expense	51.72	42.38	52.15	166.22	183.15
	Excise duty	-	-	-	-	315.92
	Other expenses	906.79	757.97	1,029.91	3,805.19	3,048.15
	Total expenses (IV)	7,585.10	6,412.53	6,383.31	29,296.50	22,520.86
V.	Profit / (Loss) before exceptional and items and tax (III - IV)	804.07	711.37	480.79	3,240.12	2,341.71
VI.	Exceptional items	-	-	-	-	-
VII.	Profit / (Loss) before tax (V - VI)	804.07	711.37	480.79	3,240.12	2,341.71
VIII	Tax expense:					
	(1) Current tax	240.40	175.00	193.00	879.00	686.00
	(2) Deferred tax	32.27	(3.50)	(37.74)	24.53	4.47
		272.67	171.50	155.26	903.53	690.47
IX	Profit/(Loss) after Tax (VII-VIII)	531.40	539.87	325.52	2,336.59	1,651.24
X	Other Comprehensive Income (net of Tax)					
	(i) Items that will not be reclassified to profit or loss	10.34	(11.89)	(5.25)	(1.38)	5.18
	(ii) Items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income (net of Tax)	10.34	(11.89)	(5.25)	(1.38)	5.18
XI	Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	541.74	527.98	320.27	2,335.21	1,656.42
	Paid up Equity Share Capital (Face value ₹ 5/- each)	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80
	Other Equity (excluding revaluation reserves)				15,207.48	13,708.72
XII	Earnings per equity share (Non annualised) (In Rs.)					
	(1) Basic	2.12	2.15	1.30	9.33	6.59
	(2) Diluted	2.12	2.15	1.30	9.33	6.59

See accompanying notes to the financial results




Note-1

Statement of Assets and Liabilities

(Rs. in Lakhs)

PARTICULARS		As at March 31, 2019	As at March 31, 2018
I	ASSETS		
1	Non-current Assets		
	(a) Fixed Assets		
	(i) Property, Plant and equipment	2,082.53	1,633.00
	(ii) Capital work-in-progress	3,385.29	591.83
	(iii) Intangible Assets	34.57	37.06
		5,502.39	2,261.89
	(b) Financial Assets		
	(i) Investments	3,003.41	3,069.57
	(ii) Loans and Advances	-	-
	(iii) Other Financial Assets	99.36	55.76
	(c) Deferred Tax Assets (Net)	90.51	114.48
	(d) Other Non Current Assets	113.62	-
	Total Non-Current Assets	8,809.29	5,501.70
2	Current Assets		
	(a) Inventories	4,285.07	3,190.40
	(b) Financial Assets		
	(i) Investments	862.04	3,556.50
	(ii) Trade receivables	7,453.45	7,092.31
	(iii) Cash and cash equivalents	727.24	379.91
	(iv) Other Bank balances	421.34	420.40
	(v) Loans and Advances	34.14	43.04
	(vi) Other financial assets	168.20	213.30
	(c) Other current assets	1,266.54	521.69
	Total Current Assets	15,218.02	15,417.55
	TOTAL ASSETS	24,027.31	20,919.26
I	EQUITY AND LIABILITIES		
	Equity		
	(i) Equity Share Capital	1,252.80	1,252.80
	(ii) Other Equity	15,207.48	13,708.72
	TOTAL EQUITY	16,460.28	14,961.52
	Liabilities		
1	NON-CURRENT LIABILITIES		
	Provisions	86.84	94.83
	TOTAL NON-CURRENT LIABILITIES	86.84	94.83
2	CURRENT LIABILITIES		
	(a) Financial Liabilities		
	(i) Borrowings	438.57	244.38
	(ii) Trade Payables:		
	Due to Micro and Small Enterprises	29.04	-
	Due to other than Micro and Small Enterprises	5,862.55	5,198.38
	(iii) Other financial liabilities	933.48	246.36
	(b) Other current liabilities	185.32	44.21
	(c) Provisions	18.62	19.65
	(d) Current Tax Liabilities(Net)	12.61	109.92
	TOTAL CURRENT LIABILITIES	7,480.19	5,862.90
	TOTAL EQUITY AND LIABILITIES	24,027.31	20,919.25

Prasad




2. The results of the quarter & year ended March 31, 2019 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 22, 2019.
3. The Board of Directors of the Company has recommended a final dividend of Rs. 2.75/- per equity share of face value of Rs. 5/- each (55%), subject to shareholders' approval in the forthcoming Annual General Meeting.
4. Revenue from operations for the quarter and year ended March 31, 2019 and quarter ended December 31, 2018 and March 31, 2018 is net of Goods and Services Tax (GST), however revenue from operations till the quarter ended June 30, 2017, included in the results for the year ended March 31, 2018, are gross of Excise Duty. Accordingly, the revenue from operations is not comparable.
5. The figures for the quarter ended March 31, 2019 and March 31, 2018 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.
6. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.
7. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Limited



Bipin N. Shah
Managing Director
(DIN: 00083244)



Place : Mumbai

Dated : May 22, 2019

Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Anuh Pharma Limited

1. We have audited the accompanying statement of financial results of Anuh Pharma Limited ('the Company') for the quarter and year ended 31st March , 2019 (' the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 ('the Circular'). The financial results for the quarter and year ended 31st March, 2019 have been prepared on the basis of the financial results for the nine-month period ended 31st December, 2018, the audited annual financial statements as at and for the year ended 31st March, 2019, and the relevant requirements of the Regulation and the Circular, which are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these financial results based on our review of the financial results for the nine-month period ended 31st December, 2018 which was prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 Interim Financial Reporting specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended 31st March, 2019; and relevant requirements of the Regulation and the Circular.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date results:
 - i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, in this regard; and
 - ii. give a true and fair view of the net profit, other comprehensive income and other financial information of the Company for the quarter and year ended 31st March, 2019.
4. Further, read with paragraph 1 above, we report that the figures for the quarter ended 31st March, 2019 represent the derived figures between the audited figures in respect of the financial year ended 31st March, 2019 and the published year-to-date figures up to 31st December, 2018, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review, as required under the Regulation and the Circular.

For JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
(FIRM REG. NO. 104133W)



V. A. Merchant

VIRAL A. MERCHANT
PARTNER
MEMBERSHIP NO. 116279

PLACE: Mumbai
DATE: 22nd May, 2019



ANUH PHARMA LTD.

3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, **MUMBAI** - 400 018. **INDIA**
Tel. : 91-22-6622 7575 • Fax : 91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

22nd May, 2019

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Fort, Mumbai – 400001

Sub: Declaration w.r.t. Audit Report with unmodified opinion to the Audited Financial Results for the financial year ended 31st March, 2019

Ref : Scrip Code No. 506260


Dear Sir,

With reference to the captioned subject and pursuant to the provisions of Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and in compliance with SEBI Circular CIR/CFD/CMD/56/2016 dated 27th May, 2016, we hereby declare that the Statutory Auditors of the Company i.e. Jayantilal Thakkar & Co., Chartered Accountants, have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the financial year ended 31st March, 2019.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,
For **Anuh Pharma Ltd**


Bipin Shah
Managing Director
(DIN: 00083244)

